Navigation Links
Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
Date:5/20/2008

Systemic Hypertension

An acute elevation of blood pressure, or acute hypertension, is a life-threatening condition that can cause permanent damage to the brain, heart, kidneys and blood vessels. It occurs in nearly 50 percent of patients presenting to the hospital with acute heart failure and is a common occurrence for patients with renal dysfunction. It is critical to rapidly manage and maintain optimal blood pressure to minimize risk of death and damage to vital organs. Of the over 35 million people in the United States with hypertension, over one million people each year will have one or more acute episodes of high blood pressure, requiring treatment in an acute care setting.

About Congestive Heart Failure (CHF)

Currently in the U.S., CHF affects nearly 5 million people with 550,000 new cases of CHF diagnosed each year. Despite the treatment of CHF with multiple drugs, almost all CHF patients will experience at least one episode of acute CHF that requires treatment with intravenous medications in the hospital. There were over 1,100,000 hospitalizations for CHF in 2004. Congestive heart failure has tremendous human and financial costs. Estimated direct costs in the U.S. for CHF were $29.6 billion in 2006.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company primarily focused on discovering and developing targeted, receptor-specific peptide and small molecule therapeutics, including melanocortin ("MC")-based therapeutics. Therapeutics affecting the activity of the MC family of receptors may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia, hemorrhagic shock and inflammation-related diseases. The Company is exploring other receptor-specific therapeutics, including natriuretic peptide receptor A ("NPRA") agonist compounds for use in treatment of acute systemic hypertension, congestive heart failure and other d
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
4. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
5. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
6. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
7. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
8. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
9. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Senesco Technologies Initiates Preclinical Studies for Cancer Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...re/ -- New research has found that the availabilit...T) scanner in an emergency room can significantly ...a potentially life-saving treatment. Results of th...NSMC)-Salem Hospital in Salem, Mass., will be pres...cal Society of North America (RSNA). , , "T...
(Date:12/1/2008)...RNewswire-USNewswire/ -- A study has found that po... for imaging the breast, is not affected by either...factors that limit the effectiveness of standard m...ll be presented today at the annual meeting of the... , "The ability of PEM to detect cancer does...
(Date:12/1/2008)...irstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: ...f the world,s leading medical journals, results of... experimental compound tasimelteon (VEC-162). The...elatonin agonist tasimelteon (VEC-162) for transie... controlled multicentre trials." Results are repor...
(Date:12/1/2008)...rgeGen has announced that an oral,presentation of...d clinical,trial of TG101348 in myeloproliferativ... American Society of Hematology (ASH) Meeting. , ...:, Title: A Phase I Study of TG... JAK2-Selective Inhibitor, in Patients with,...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Helix BioPharma Announces 2411 4 Million Private Placement 7982 1Helix BioPharma Announces 2411 4 Million Private Placement 7982 2New England Peptide Names Director of Chemical Development 7977 1New England Peptide Names Director of Chemical Development 7977 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 1LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 3Kazak apple research key to preventing blue mold 5127 1Kazak apple research key to preventing blue mold 5127 2
...al Meeting of the American,Psychiatric Association... -- In adults with,major depressive disorder, addi...sulted in significant improvement in the primary,e...Scale (MADRS),Total Score. In this six-week, rando...the 160th Annual Meeting of the American,Psychiatr...
...ewswire/ -- Sirion Therapeutics,Inc., an ophthalm...day that it has received orphan drug designation f... anti-viral therapy,ganciclovir, for the treatmen...ently marketed by Laboratoires Thea in Europe unde... rights to,Virgan(R) for the United States from La...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2
(Date:12/2/2008)... At this year,s ASHP midyear meeting...rusted distributor of critical-care biopharmaceuti...model for supply chain integrity and demonstrate h...on to a new level. (Booth #1439) , ...,s ASHP midyear meeting, FFF Enterprises, the nati...
(Date:12/2/2008)... Marathon Health, a leading provider...s, has announced that New Balance, the athletic pr...velop, implement and manage onsite health clinics ...alance facilities in Maine , ...athon Health, a leading provider of onsite employe...
(Date:12/2/2008)... Does your over-the-phone interpreta... after you have completed the call? , ...2008 -- In the world of over-the-phone interpretat...OPI, a second over one minute can add up over the ...ding. When an organization employs an over-the-pho...
(Date:12/2/2008)... For many families, the problem with... Koch provides insight into how caregivers of agin...to the elder care experience. , ...or many families the stress of the holiday season ...t and elder care expert Esther Koch , founder of ...
Breaking Medicine News(10 mins):Health News:FFF Enterprises Unveils ‘The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 2Health News:FFF Enterprises Unveils ‘The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 3Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 2Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3
...troke victims to bust blood clots may help treat s... according to a study published Monday. While tre... significantly in the last 25 years, it has largel...tbite, say the authors of the article published in...
...f an unarmed man on his wedding day, the New York ...halyzer tests after such shootings. Sean Bell, a 2... girlfriend, died in a hail of 50 bullets hours be...ar. Police opened fire on Bells car outside a top...
...on for cancer patients who have to spend weeks in ...ase of Nick Gall-Tomassen, aged 31, suffering fro...on time away from the ward. His backpack holds re...t into his body through a vein in his arm. Nick sa...
... Heart Center helps explain excessive body weight ...body weight is associated with a thickening of the...mping chamber. Known to physicians as left ventric...can lead to heart failure and rhythm problems. &#...
Other Medicine News:Health News:Frostbite can Be Treated by Bloodclot Drug 2Health News:Breathalyzer Tests for Cops Involved in Shootings 2Health News:Special Backpacks Provide Much Needed Relief for Cancer Patients 2
Avant E-Z Rack Premium Low Binding 10 l Microreach Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone.
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Medicine Products: